The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Phase 3 Not yet recruiting 90 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to \<18 years with moderate-to-Severe plaque psoriasis

Timeline

Start: 2025-02
Primary completion: 2026-07
Completion: 2026-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	vunakizumab	Protein / enzyme biologic	—	Subcutaneous

Indications

No indication recorded.